Copyright © 1999 by the European Society of Cardiology.
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty
Final results of the fluvastatin angiographic restenosis (FLARE) trial
a Thoraxcenter, Erasmus University Hospital, Rotterdam, The Netherlands
b Guy’s Hospital, London, U.K.
c Catharina Hospital, Eindhoven, The Netherlands
d University Hospital San Carlos, Madrid, Spain
e St Jans Hospital, Genk, Belgium
f Cardiology Institute, Bologna University, Bologna, Italy
g Royal Infirmary, Glasgow, U.K.
h Ziekenhuis De Weezenlanden, Zwolle, The Netherlands
i Cardialysis, Rotterdam, The Netherlands
j Novartis Pharma AG. Basel, Switzerland
accepted May 28, 1998
Abstract
Background
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation. Experimental evidence suggests that fluvastatin may, independent of any lipid lowering action, exert a greater direct inhibitory effect on proliferating vascular myocytes than other statins. The FLARE (Fluvastatin Angioplasty Restenosis) Trial was conceived to evaluate the ability of fluvastatin 40mg twice daily to reduce restenosis after successful coronary balloon angioplasty (PTCA).
Methods
Patients were randomized to either placebo or fluvastatin 40mg twice daily beginning 2–4 weeks prior to planned PTCA and continuing after a successful PTCA (without the use of a stent), to follow-up angiography at 26±2 weeks. Clinical follow-up was completed at 40 weeks. The primary end-point was angiographic restenosis, measured by quantitative coronary angiography at a core laboratory, as the loss in minimal luminal diameter during follow-up. Clinical end-points were death, myocardial infarction, coronary artery bypass graft surgery or re-intervetion, up to 40 weeks after PTCA.
Results
Of 1054 patients randomized, 526 were allocated to fluvastatin and 528 to placebo. Among these, 409 in the fluvastatin group and 427 in the placebo group were included in the intention-to-treat analysis, having undergone a successful PTCA after a minimum of 2 weeks of pre-treatment. At the time of PTCA, fluvastatin had reduced LDL cholesterol by 37% and this was maintained at 33% at 26 weeks. There was no difference in the primary end-point between the treatment groups (fluvastatin 0·23±0·49mm vs placebo 0·23±0·52mm,P=0·95) or in the angiographic restenosis rate (fluvastatin 28%, placebo 31%, chi-squareP=0·42), or in the incidence of the composite clinical end-point at 40 weeks (22·4% vs 23·3%; logrankP=0·74). However, a significantly lower incidence of total death and myocardial infarction was observed in six patients (1·4%) in the fluvastatin group and 17 (4·0%) in the placebo group (log rankP=0·025).
Conclusion
Treatment with fluvastatin 80mg daily did not affect the process of restenosis and is therefore not indicated for this purpose. However, the observed reduction in mortality and myocardial infarction 40 weeks after PTCA in the fluvastatin treated group has not been previously reported with statin therapy. Accordingly, a priori investigation of this finding is indicated and a new clinical trial with this intention is already underway.
Key Words: Prevention of restenosis, fluvastatin, balloon angioplasty
f1 Correspondence: Prof. P. W. Serruys, MD, PhD, Thoraxcenter Bd 418, Academic Hospital, Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Patel, M. H. Shishehbor, and D. L. Bhatt A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis Eur. Heart J., March 2, 2007; 28(6): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kamishirado, T. Inoue, M. Sakuma, T. Tsuda, T. Hayashi, K. Takayanagi, and K. Node Effects of Statins on Restenosis After Coronary Stent Implantation Angiology, February 1, 2007; 58(1): 55 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Pascual, J. M. Arribas, P. L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas, and M. Valdes Preoperative Statin Therapy and Troponin T Predict Early Complications of Coronary Artery Surgery Ann. Thorac. Surg., January 1, 2006; 81(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kaehler, R. Koester, W. Billmann, C. Schroeder, H.-J. Rupprecht, T. Ischinger, R. Jahns, A. Vogt, M. Lampen, R. Hoffmann, et al. 13-year follow-up of the German angioplasty bypass surgery investigation Eur. Heart J., October 2, 2005; 26(20): 2148 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E Delea, T. A Jacobson, P. W. Serruys, J. S Edelsberg, and G. Oster Cost-Effectiveness of Fluvastatin Following Successful First Percutaneous Coronary Intervention Ann. Pharmacother., April 1, 2005; 39(4): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur. Heart J., October 1, 2004; 25(19): 1679 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Niroomand, O Hauer, C P Tiefenbacher, H A Katus, and W Kuebler Influence of alcohol consumption on restenosis rate after percutaneous transluminal coronary angioplasty and stent implantation Heart, October 1, 2004; 90(10): 1189 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z.H. Rittersma, R. J. de Winter, K. T. Koch, C. E. Schotborgh, M. Bax, G. S. Heyde, J. P. van Straalen, K. J. Mulder, J. G.P. Tijssen, G. T. Sanders, et al. Preprocedural C-Reactive Protein Is Not Associated with Angiographic Restenosis or Target Lesion Revascularization after Coronary Artery Stent Placement Clin. Chem., September 1, 2004; 50(9): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wilt, H. E. Bloomfield, R. MacDonald, D. Nelson, I. Rutks, M. Ho, G. Larsen, A. McCall, S. Pineros, and A. Sales Effectiveness of Statin Therapy in Adults With Coronary Heart Disease Arch Intern Med, July 12, 2004; 164(13): 1427 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Bae, E. Bassenge, K.-Y. Kim, Y.-C. Synn, k.-R. Park, and M. Schwemmer Effects of Low-Dose Atorvastatin on Vascular Responses in Patients Undergoing Percutaneous Coronary Intervention With Stenting Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 185 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R Sindermann, V. Verin, J. W Hopewell, H. P. Rodemann, and J. H Hendry Biological aspects of radiation and drug-eluting stents for the prevention of restenosis Cardiovasc Res, July 1, 2004; 63(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Cipollone, M Fazia, A Iezzi, B Pini, F Costantini, D De Cesare, L Paloscia, G Materazzo, E D'Annunzio, T Bucciarelli, et al. High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis Heart, July 1, 2003; 89(7): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Thompson, P. Clarkson, and R. H. Karas Statin-Associated Myopathy JAMA, April 2, 2003; 289(13): 1681 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Mercado, W Maier, E Boersma, C Bucher, V de Valk, W.W O'Neill, B.J Gersh, B Meier, P.W Serruys, and W Wijns Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting: Implications for mechanical plaque sealing Eur. Heart J., March 2, 2003; 24(6): 541 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, J. Mehilli, H. Holle, K. Hosl, D. Kastrati, J.u. Pache, M. Seyfarth, F.-J. Neumann, J. Dirschinger, and A. Kastrati Statin treatment following coronary artery stenting and one-year survival J. Am. Coll. Cardiol., September 4, 2002; 40(5): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
P. W. J. C. Serruys, P. de Feyter, C. Macaya, N. Kokott, J. Puel, M. Vrolix, A. Branzi, M. C. Bertolami, G. Jackson, B. Strauss, et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, June 26, 2002; 287(24): 3215 - 3222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Palinski and S. Tsimikas Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1673 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Ruygrok, M. W.I. Webster, V. de Valk, G.-A. van Es, J. A. Ormiston, M.-A. M. Morel, and P. W. Serruys Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention Circulation, November 6, 2001; 104(19): 2289 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mercado, E. Boersma, W. Wijns, B. J. Gersh, C. A. Morillo, V. de Valk, G.-A. van Es, D. E. Grobbee, and P. W. Serruys Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era J. Am. Coll. Cardiol., September 1, 2001; 38(3): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal Lipid Disorders : Justification of Methods and Goals of Treatment Chest, September 1, 2001; 120(3): 979 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
|
|
A. Kastrati and A. Schomig Good medicines for bad genes Eur. Heart J., April 1, 2001; 22(7): 523 - 525. [PDF]
|
|
|
|
 |
|
 S. Bandyopadhyay, A.J. Bayer, and M.S. O'Mahony Age and gender bias in statin trials QJM, March 1, 2001; 94(3): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sabate, M. A. Costa, K. Kozuma, I. P. Kay, C. J. van der Wiel, V. Verin, W. Wijns, P. W. Serruys, and on behalf of the Dose Finding Study Group Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, D. P. Foley, B. Hofling, J. Puel, H. D. Glogar, R. Seabra-Gomes, J. Goicolea, P. Coste, W. Rutsch, H. Katus, et al. Carvedilol for Prevention of Restenosis After Directional Coronary Atherectomy : Final Results of the European Carvedilol Atherectomy Restenosis (EUROCARE) Trial Circulation, April 4, 2000; 101(13): 1512 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst Experience and Reason Chest, January 1, 2000; 117(1): 2 - 5. [Full Text] [PDF]
|
|
|
|
|
|
A. Corsini Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175. [Abstract] [PDF]
|
|
|
|
|
|
P.J. de Feyter Editorials: Lipids and coronary restenosis: an elusive link Eur. Heart J., October 1, 1999; 20(19): 1371 - 1374. [PDF]
|
|
|
|
|
|
B Jorgensen, S Simonsen, K Endresen, K Forfang, T Egeland, A.T Hostmark, and E Thaulow Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids Eur. Heart J., October 1, 1999; 20(19): 1407 - 1414. [Abstract] [PDF]
|
|
|
|
|
|
A. W. Chan, D. L. Bhatt, D. P. Chew, M. J. Quinn, D. J. Moliterno, E. J. Topol, and S. G. Ellis Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention Circulation, February 12, 2002; 105(6): 691 - 696. [Abstract] [Full Text] [PDF]
|
|